COMFORTABLE, HEALTHY, STABLE VISION: IT MAY BE ALL IN YOUR EYELIDS

Meibomian Gland Dysfunction (MGD): Restore Gland Function Before It Regresses

What Is Meibomian Gland Dysfunction (MGD)?

Healthy Meibomian glands secrete oil with every blink. This oil, or lipid, serves as a critical component of a healthy tear film.

When the glands are not functioning correctly, it is called Meibomian Gland Dysfunction, or MGD. MGD is a leading cause of Dry Eye Disease and can be the source of dry eye symptoms, such as burning, stinging, and itching.

What Causes MGD?

MGD is caused by a change in the Meibomian glands. If left untreated, MGD is a chronic progressive condition and may worsen over time, leaving eyes feeling more irritated, inflamed, and dry.¹

MEIBOMIAN GLANDS



While eye drops may temporarily soothe some symptoms of Dry Eye Disease, they do not remove Meibomian gland obstuctions.

86% of patients with a diagnosis of dry eye also had MGD, in one study.²

1in5 MGD patients may have no symptoms.³

What Do Meibomian Glands Look Like?



NORMAL GLAND STRUCTURE



SHORTENED GLANDS & GLAND LOSS



SIGNIFICANT GLAND LOSS

One component of an evaluation for MGD

can include an image of the eyelid, showing complete gland structure and Meibomian gland loss.

TREAT BEFORE SYMPTOMS BEGIN

Maintaining healthy function and structure of your Meibomian glands before you become symptomatic is key, as MGD is a chronic, progressive and obstructive condition.⁹⁻¹⁰

If you are diagnosed with MGD, there's something you can do about it. Early detection and treatment can minimize its long term negative impact.

REFERENCES

1. Nichols KK, Foulks GN, Bron AJ, et al. The international workshop on meibomian gland dysfunction: executive summary. *Invest Ophthalmol Vis Sci.* 2011;52(4):1922-9. 2. Lemp MA, Crews LA, Bron AJ, Foulks GN, Sullivan BD. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. *Cornea.* 2012 May;31(5):472-478. 3. Viso E, Rodríguez-Ares MT, Abelenda D, Oubiña B, Gude F. Prevalence of asymptomatic and symptomatic meibomian gland dysfunction in the general population of Spain. *Invest Ophthalmol Vis* Sci. 2012; 53(6): 2601 - 2606. doi: 10.1167/iovs.11-9228. 4. Duke University website. Immune response likely culprit in eyelid gland condition that causes dry eye. Found at: https://dukeeyecenter.duke.edu/news-events/immune-response-likely-culprit-eyelid-gland-condition-causes-dry-eye, July 2018. Accessed December 10, 2019. 5. American Optometric Association, Paraoptometric Resource Center, CPC Submission, T Petrosyan. Cosmetics and the eye: how your beauty products could be harming your eyes. Found at: https://www.aoa.org/Documents/CPC%20SUBMIS-SION%20%20Cosmetics%20and%20the%20Eye%20How%20Your%20Beauty%20Products%20Could%20Be%20Harming%20Your%20Eyes.pdf 2018. Accessed December 10, 2019. 6. Machalinska A, Zakrzewska A, Adamek B, et al. Comparison of morphological and functional meibomian ed risk factors for, MGD. Invest Ophthalmol Vis Sci. 2011 Mar;52(4):1994-2005.

COMMON CONDITIONS THAT CONTRIBUTE TO MGD

| Computer/ device use | Contact lens wear |
|--|---|
| Allergies | Eye infections (such as styes)⁴ |
| Environment | Medications |
| Reading/ watching TV | Eye surgery |
| Glaucoma and chronic eye diseases | Climate |
| Poor blinking | Makeup that can clog glands⁵ |
| SINGLE STUDIES SHOW MGD WAS PREVALENT IN | |
| 60% of Contact Lens Wearers ⁶ | 79% of Perimenopausal Women |
| 58% of Diabetics | |
| 80% of Glaucoma Patients ⁷ | 52% of Cataract Patients ⁸ |

A HEALTHY CORNEAL SURFACE CAN SIGNIFICANTLY IMPROVE SURGICAL OUTCOMES

If you've been diagnosed with MGD, treating your MGD prior to surgery can optimize your ocular surface and improve chances for surgical success.

Dry Eye Disease caused by MGD can cause unsatisfactory vision and affect the overall results of both cataract and LASIK surgery.¹¹ If you have dry eye symptoms caused by MGD, these symptoms tend to worsen with surgical procedures.¹¹ Treating MGD with LipiFlow[®] optimizes the ocular surface by stabilizing the tear film, an important step prior to surgery.¹¹

Potential Risks Associated with Leaving MGD Untreated Before Surgery

- Leaving MGD untreated may delay your ability to have cataract or LASIK surgery.¹³
- Postoperative worsening of MGD symptoms such as redness and pain and could result in complications such as unsatisfactory or fluctuating vision and infection.¹³

THE LIPIFLOW[®] PULSATION SYSTEM: PROVEN TREATMENT FOR MGD

A treatment for your eyelids, this effective combination of heat and pressure is typically performed while resting in a chair in your ophthalmologist's office.

- The LipiFlow[®] Treatment is a safe and FDA-cleared,¹⁴ in-office procedure for the treatment of MGD.
- After an initial anesthetic eye drop, Meibomian glands are heated and then gently massaged to loosen the oil trapped within the glands.
- The contents are pushed up and out while protecting the delicate structure of the eye.

Functioning oil gland secretion

CAUTION: Federal law restricts this device to sale by or on the order of a licensed physician. INDICATIONS AND IMPORTANT SAFETY INFORMATION for LipiFlow® Thermal Pulsation System

INDICATIONS: The LipiFlow® Thermal Pulsation System is intended for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction (MGD), also known as evaporative dry eye or lipid deficiency dry eye. CONTRAINDICATIONS: Do not use the LipiFlow® System in patients with the following conditions. Use of the device in patients with these conditions. Coular surgery within prior 3 months, including intraocular, oculo-plastic, corneal or refractive surgery procedure. Ocular injury within prior 3 months. Ocular surgery within prior 3 months. Coular surface abnormality that may could, lacrimal gland, lacrimal sac, or eyelids including a hordeolum or stye). Active ocular inflammation or history of chronic, recurrent ocular inflammation within prior 3 months (e.g., retinitis, macular inflammation choroiditis, uveitis, initis, seleritis, episcleritis, episcleritis, peiscleritis, peiscleritis, peiscleritis, such as eyes with small palpebral fornices. Use of the LipiFlow® System in patients with the following conditions may result in reduced treatment effectiveness because these conditions. Moderate to severe (Grade 2-4) allergic, vernal or giant papillary conjunctivitis. Severe (Grade 3 or 4) eyelid inflammation (e.g., blepharochaasis, staphylococcal blepharitis or seborrheic blepharitis). Patients with severe eyelid inflammation should be treated medically prior to device use. Systemic disease conditions that cause dry eye (e.g., stevens-Johnson syndrome, vitamin A deficiency, theumatola, describer and systemic anthritis, Wingener's granulomatosis, sarcoidosis, luelpharophasy, luels eritopian, adystemic anthritistamines). Esthetic eyelid and eyelash procedures (e.g., blepharophasy), luse retained may cause. Systemic disease conditions with ease or diverse as result of the procedure syndrome, systemic upus erithematosus, syndrome, systemic upus erithematosus, syndrome, as evere eyelid inflammation (e.g., stevens-Johnson syndrome,

REFERENCES

11. Starr C, Gupta P, Farid M, Beckman K, Chan C, FRCSC, Yeu E, Gomes J, Ayers B, Berdahl J, Holland E, Kim T, Francis M, the ASCRS Cornea Clinical Committee. An algorithm for the preoperative diagnosis and treatment of ocular surface disorders. ASCRS and ESCRS. 2019; 45(5): 669-684. doi.org/10.1016/j.jcrs.2019.03.023 12. Data on File 2018 (NCT01808560). Pilot Study for Treatment of Meibomian Gland Dysfunction (MGD) Prior to Cataract Surgery. Accessed from https://clinicaltrials.gov/show/NCT1808560, NIH U.S. National Library of Medicine ClinicalTrials.gov. website. Randomized, parallel group, open-label trial, n=34 subjects in the US (ages 55-84 years) who had evidence of MGD and who were planning to undergo bilateral cataract surgery. 13. ASCRS Cornea Clinical Committee. An algorithm for the preoperative diagnosis and treatment of ocular surface disorders. *J Cataract Refract Surg* 2019; 45: 669-84. 14. K161357, 510K Summary. 15. Internal data on file. 16. Blackie CA et al. The sustained effect (12 months) of a single-dose vectored thermal pulsation procedure for meibomian gland dysfunction and evaporative dry eye. Clinical Ophthalmol. 2016; 10:1385-1396 17. Lane SS et al. A New System, the LipiFlow, for the Treatment of Meibomian Gland Dysfunction (MGD). *Cornea*. 2012;31(4):396-404. 18. Blackie CA, Carlson AN, Korb, DR. Treatment for meibomian gland dysfunction and dry eye symptoms with a single-dose vectored thermal pulsation: a review. *Curr Opin Ophthalmol*. 2015;26(4):306-13.

© 2020 Johnson & Johnson Surgical Vision, Inc. All other trademarks are the intellectual property of their respective owners. PP2020TS4051





Study Demonstrates Treating MGD with LipiFlow® prior to Surgery Reduces Dry Eye Symptoms such as Burning or Grittiness, Post-Op and Improves Meibomian Gland Function for Cataract Patients¹²

• 2X SYMPTOM REDUCTION LipiFlow[®] treated patients had a 2-fold reduction in dry eye symptoms 3 months after surgery¹²

With more than 400,000 treatments worldwide and growing, patients are experiencing proven benefits from the LipiFlow[®] Thermal Pulsation System.¹⁵

- Long lasting results; many see the continued benefit for up to 12 months¹⁶
- A majority of patients reported no pain/or significant discomfort during treatment¹⁷

NOTE: Results with LipiFlow[®] can be experienced 6-8 weeks after treatment and may vary depending on the level of severity of MGD.¹⁸ Because LipiFlow[®] treats MGD, Dry Eye Disease symptoms are not expected to fully resolve with LipiFlow[®]. Dry Eye Disease is a multifactorial condition and may require additional treatment. Be sure to talk to your doctor about what's right for you.



www.dryeyeandmgd.com